TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury

作者：Wenjing Zhong, Tian Liu, Hui‐Hui Yang, Jia‐Xi Duan, Jintong Yang, Xinxin Guan, Jian‐Bing Xiong, Yanfeng Zhang, Chen‐Yu Zhang, Yong Zhou, Cha‐Xiang Guan · 发表于：International Journal of Biological Sciences · 年份：2022 · DOI：10.7150/ijbs.77304 · 被引用次数：168 · 研究领域：Inflammation biomarkers and pathways、Inflammasome and immune disorders、Respiratory Support and Mechanisms

The triggering receptor expressed on myeloid cells-1 (TREM-1) is a pro-inflammatory immune receptor potentiating acute lung injury (ALI). However, the mechanism of TREM-1-triggered inflammation response remains poorly understood. Here, we showed that TREM-1 blocking attenuated NOD-, LRRand pyrin domain-containing 3 (NLRP3) inflammasome activation and glycolysis in LPS-induced ALI mice. Then, we observed that TREM-1 activation enhanced glucose consumption, induced glycolysis, and inhibited oxidative phosphorylation in macrophages. Specifically, inhibition of glycolysis with 2-deoxyglucose diminished NLRP3 inflammasome activation of macrophages triggered by TREM-1. Hypoxia-inducible factor-1 (HIF-1) is a critical transcriptional regulator of glycolysis. We further found that TREM-1 activation facilitated HIF-1 accumulation and translocation to the nucleus via the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Inhibiting mTOR or HIF-1 also suppressed TREM-1-induced metabolic reprogramming and NLRP3/caspase-1 activation. Overall, the mTOR/HIF-1/glycolysis pathway is a novel mechanism underlying TREM-1-governed NLRP3 inflammasome activation. Therapeutic targeting of the mTOR/HIF-1/glycolysis pathway in TREM-1-activated macrophages could be beneficial for treating or preventing inflammatory diseases, such as ALI.